The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Atara Biotherapeutics, Inc. | Common Stock | 046513107 | 26,949 | 1,876,650 | SH | SOLE | 1,876,650 | 0 | 0 | ||
Rapt Therapeutics, Inc. | Common Stock | 75382E109 | 43,225 | 1,947,063 | SH | SOLE | 1,947,063 | 0 | 0 | ||
Twilio Inc. | Class A Common Stock | 90138F102 | 63,609 | 186,667 | SH | SOLE | 186,667 | 0 | 0 | ||
Upstart Holdings, Inc. | Common Stock | 91680M107 | 98,321 | 847,788 | SH | SOLE | 847,788 | 0 | 0 |